Lancet Diabetes Endocrinol. 2021 Dec;9(12):837-846. doi: 10.1016/S2213-8587(21)00263-1. Epub 2021 Oct 28.
Randomised trials of vitamin D supplementation for cardiovascular disease and all-cause mortality have generally reported null findings. However, generalisability of results to individuals with low vitamin D status is unclear. We aimed to characterise dose-response relationships between 25-hydroxyvitamin D (25[OH]D) concentrations and risk of coronary heart disease, stroke, and all-cause mortality in observational and Mendelian randomisation frameworks.
Observational analyses were undertaken using data from 33 prospective studies comprising 500 962 individuals with no known history of coronary heart disease or stroke at baseline. Mendelian randomisation analyses were performed in four population-based cohort studies (UK Biobank, EPIC-CVD, and two Copenhagen population-based studies) comprising 386 406 middle-aged individuals of European ancestries, including 33 546 people who developed coronary heart disease, 18 166 people who had a stroke, and 27 885 people who died. Primary outcomes were coronary heart disease, defined as fatal ischaemic heart disease (International Classification of Diseases 10th revision code I20-I25) or non-fatal myocardial infarction (I21-I23); stroke, defined as any cerebrovascular disease (I60-I69); and all-cause mortality.
Observational analyses suggested inverse associations between incident coronary heart disease, stroke, and all-cause mortality outcomes with 25(OH)D concentration at low 25(OH)D concentrations. In population-wide genetic analyses, there were no associations of genetically-predicted 25(OH)D with coronary heart disease, stroke, or all-cause mortality. However, for the participants with vitamin D deficiency (25[OH]D concentration <25 nmol/L), genetic analyses provided strong evidence for an inverse association with all-cause mortality (odds ratio [OR] per 10 nmol/L increase in genetically-predicted 25[OH]D concentration 0·69 [95% CI 0·59-0·80]; p<0·0001) and non-significant inverse associations for stroke (0·85 [0·70-1·02], p=0·09) and coronary heart disease (0·89 [0·76-1·04]; p=0·14). A finer stratification of participants found inverse associations between genetically-predicted 25(OH)D concentrations and all-cause mortality up to around 40 nmol/L.
Stratified Mendelian randomisation analyses suggest a causal relationship between 25(OH)D concentrations and mortality for individuals with low vitamin D status. Our findings have implications for the design of vitamin D supplementation trials, and potential disease prevention strategies.
British Heart Foundation, Medical Research Council, National Institute for Health Research, Health Data Research UK, Cancer Research UK, and International Agency for Research on Cancer.
随机维生素 D 补充剂治疗心血管疾病和全因死亡率的试验通常报告无显著结果。然而,其结果对维生素 D 状态较低的个体的普遍性尚不清楚。我们旨在描述观察性和孟德尔随机化研究中 25-羟维生素 D(25[OH]D)浓度与冠心病、中风和全因死亡率之间的剂量-反应关系。
使用来自 33 项前瞻性研究的数据进行观察性分析,这些研究共纳入了 500962 名基线时无冠心病或中风病史的个体。在四项基于人群的队列研究(英国生物库、EPIC-CVD 和两个哥本哈根基于人群的研究)中进行了孟德尔随机化分析,这些研究共纳入了 386406 名欧洲血统的中年个体,其中 33546 人发生了冠心病,18166 人发生了中风,27885 人死亡。主要结局是冠心病,定义为致命性缺血性心脏病(国际疾病分类第 10 次修订版代码 I20-I25)或非致命性心肌梗死(I21-I23);中风,定义为任何脑血管疾病(I60-I69);以及全因死亡率。
观察性分析表明,在低 25(OH)D 浓度时,25(OH)D 浓度与新发冠心病、中风和全因死亡率呈负相关。在全人群的遗传分析中,遗传预测的 25(OH)D 与冠心病、中风或全因死亡率之间没有关联。然而,对于维生素 D 缺乏症患者(25[OH]D 浓度<25nmol/L),遗传分析提供了强有力的证据表明,全因死亡率与 25(OH)D 浓度呈负相关(每增加 10nmol/L 遗传预测的 25[OH]D 浓度,比值比 [OR]为 0.69 [95%CI 0.59-0.80];p<0.0001),与中风(0.85 [0.70-1.02],p=0.09)和冠心病(0.89 [0.76-1.04];p=0.14)呈非显著负相关。对参与者的更精细分层发现,遗传预测的 25(OH)D 浓度与全因死亡率之间存在负相关,直至约 40nmol/L。
分层孟德尔随机化分析表明,维生素 D 状态较低的个体的 25(OH)D 浓度与死亡率之间存在因果关系。我们的研究结果对维生素 D 补充剂试验的设计和潜在的疾病预防策略具有重要意义。
英国心脏基金会、医学研究理事会、国家卫生研究院、英国健康数据研究署、英国癌症研究署和国际癌症研究机构。